Mitomycin Medac (Mitomycin)

Mitomycin belongs to the antineoplastic antibiotic class and functions by cross‑linking DNA strands. This prevents DNA replication and transcription, leading to cell cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The specific dose and schedule of Mitomycin Medac are determined by the prescribing oncologist based on the patient’s clinical condition, tumour characteristics, and renal function. No standard dose is provided here.

The pregnancy category for Mitomycin is unknown, and animal data suggest potential fetal harm. It is therefore contraindicated in pregnancy and breastfeeding unless the benefits clearly outweigh the risks, and effective contraception is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mitomycin is a chemotherapeutic agent that directly damages DNA, while Bacillus Calmette‑Guérin (BCG) is an immunotherapy that stimulates a local immune response. Mitomycin typically has a shorter treatment course and fewer systemic immune‑related side effects, whereas BCG may be preferred for high‑risk disease but carries a higher risk of infection‑related complications.

Mitomycin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light and moisture, and keep it out of reach of children. Handling requires standard aseptic technique to avoid contamination.

Mitomycin is given as an intravesical instillation. After a transurethral resection, the solution is introduced into the bladder via a catheter and retained for a prescribed dwell time, usually ranging from one to two hours, under the supervision of a qualified healthcare professional.

The most serious adverse events include severe hemorrhagic cystitis, profound bone‑marrow suppression leading to neutropenia or thrombocytopenia, renal toxicity, and rare pulmonary fibrosis. Prompt recognition and supportive care are essential to mitigate these risks.

Mitomycin is contraindicated in patients with severe renal impairment, active uncontrolled infections, known hypersensitivity to the drug, and in pregnant or breastfeeding women. Caution is also advised for individuals with prior pelvic radiation or existing bone‑marrow disorders.